Patents by Inventor Christopher John Wallis

Christopher John Wallis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHS OF TRIAZOLE ANTIFUNGAL COMPOUND PC945
    Publication number: 20230028714
    Abstract: The invention relates to crystalline polymorphic manifestations of a compound of formula (I) and related aspects.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 26, 2023
    Applicant: Pulmocide Limited
    Inventors: Christopher John WALLIS, Gerald STEELE, Suzanne BUTTAR, Osama SULEIMAN, Julian NORTHEN, John MYKYTIUK, Jamie MARSHALL
  • Novel Processes
    Publication number: 20120220779
    Abstract: The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Inventors: Claire Frances Crawford, Sandrine Garcia, Jonathan Paul Graham, Sandra Jane Harling, Nicholas Paul Henley, Stephen Andrew Hermitage, John Howard Hutchinson, Trevor Raymond Keel, Andrew Kennedy, Andrew McMurtrie Mason, Mark Simon Scott, Neil Michael Smith, Nicholas Simon Stock, Yuichi Tateno, Leontine Saskia Trouw, Peter Graham Turner, Christopher John Wallis, Robert David Willacy
  • Process for the synthesis of chloropurine intermediates
    Patent number: 6646125
    Abstract: The present invention relates to a process for the preparation of a carbocyclic purine nucleoside analogue of formula (I), its salts and pharmaceutically acceptable derivatives thereof which comprises hydrolysing a compound of formula (IV) wherein P is a protecting group, in the presence of an acid, condensing the product of formula (V) formed in situ in the presence of a base with a compound of formula (VI) followed by in situ ring closure of the resulting intermediate.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: November 11, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Martin Francis Jones, Christopher John Wallis
  • Process for preparing enantiomerically enriched N-derivatized lactams
    Patent number: 6340587
    Abstract: The present invention relates to a process for the preparation of enantiomerically enriched N-derivatized (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-ones by use of an enzyme.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: January 22, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael John Dawson, Mahmoud Mahmoudian, Christopher John Wallis
  • Carbocyclic nucleoside hemisulfate and its use in treating viral infections
    Patent number: 6294540
    Abstract: The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate of it is used in the treatment of viral infections.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: September 25, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alastair Couper Brodie, Martin Francis Jones, John Frederick Seager, Christopher John Wallis
  • Process for resolving mixtures of carbocyclic stereoisomers
    Patent number: 6147254
    Abstract: A process for the preparation of carbocyclic stereoisomers of formulae (I), (I'), (IIA'), (IIB'), (VA') and (VB'), including enantiomerically pure (IIA'), (I) and (I') utilizing fractional crystallization of salts formed with a chiral base; a reducing agent; a protecting group removing agent or a protecting group providing agent.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: November 14, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Barry Riddle Sickles, Kenneth James Ingold, Christopher John Wallis